Chronic Hepatitis C
Conditions
Keywords
chronic hepatitis C, Interferon, Ribavirin, Clinical outcome
Brief summary
This study was a clinical observational cohort study of two-way, non-intervention long-term dynamic follow-up. Enrolled in the Department of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, with interferon combined with ribavirin (PR) antiviral therapy (PR treatment greater than or equal to 6 months) and/or direct acting antivirals (DAAs) In patients with chronic hepatitis C, the baseline, antiviral treatment and withdrawal follow-up data before the antiviral treatment were collected, and the patients were followed up for 3-6 months. Clinical data such as clinical biochemistry, HCV RNA and serological markers (anti-HCV), AFP and liver imaging (liver ultrasound) were collected during the study period. At least 144 weeks of observation on the virological response and clinical outcome of anti-viral treatment of chronic hepatitis C, the main evaluation index of liver cancer and decompensated liver cirrhosis after stopping the drug, and exploring the antiviral treatment of patients Long-term virological response and clinical outcomes, clarifying their influencing factors.
Detailed description
This study was a clinical observational cohort study of two-way, non-intervention long-term dynamic follow-up. Enrolled in the Department of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, with interferon combined with ribavirin (PR) antiviral therapy (PR treatment greater than or equal to 6 months) and/or direct acting antivirals (DAAs) In patients with chronic hepatitis C, the baseline, antiviral treatment and withdrawal follow-up data before the antiviral treatment were collected, and the patients were followed up for 3-6 months. Clinical data such as clinical biochemistry, HCV RNA and serological markers (anti-HCV), AFP and liver imaging (liver ultrasound) were collected during the study period. At least 144 weeks of observation on the virological response and clinical outcome of anti-viral treatment of chronic hepatitis C, the main evaluation index of liver cancer and decompensated liver cirrhosis after stopping the drug, and exploring the antiviral treatment of patients Long-term virological response and clinical outcomes, clarifying their influencing factors.
Interventions
DRUGInterferon
Interferon combined with ribavirin antiviral therapy
DRUGribavirin
Interferon combined with ribavirin antiviral therapy
DRUGDAAs
DAAs antiviral treatment
Sponsors
Beijing Ditan Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Chronic hepatitis C patients treated with interferon plus ribavirin (PR) antiviral therapy (PR treatment greater than or equal to 6 months) and/or direct antiviral drugs (DAAs)
Exclusion criteria
* Co-infected with hepatitis B virus or human immunodeficiency virus * Had an autoimmune disease, liver tumour, or severe cardiac disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of liver cancer | up to 144 weeks | The incidence of liver cancer after anti-viral treatment of chronic hepatitis C |
| The incidence of decompensated cirrhosis | up to 144 weeks | The incidence of decompensated cirrhosis after anti-viral treatment of chronic hepatitis C |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of persistent virological response or relapse | up to 144 weeks | Percentage of persistent virological response or relapse after antiviral therapy for chronic hepatitis C |
| Related factors of liver cancer | up to 144 weeks | Related factors including viral indicators (HCV RNA content, anti-HCV), clinical biochemical indicators (ALT, AST, ALB, Tbil), blood routine and coagulation function indicators (PTA) and serum AFP and liver ultrasound results of liver cancer after anti-viral treatment of chronic hepatitis C |
| Related factors of decompensated cirrhosis | up to 144 weeks | Related factors including viral indicators (HCV RNA content, anti-HCV), clinical biochemical indicators (ALT, AST, ALB, Tbil), blood routine and coagulation function indicators (PTA) and serum AFP and liver ultrasound results of decompensated cirrhosis after anti-viral treatment of chronic hepatitis C |
Countries
China
Contacts
Primary ContactYao Xie, doctor
Outcome results
None listed